GLP-1 TirzepatideRx

All-in monthly price at 10 mg — medication plus any membership fee

Home News Membership stacking spreads: the advertised pric

Membership stacking spreads: the advertised price is increasingly not the price

Several programs now split the charge into medication plus a mandatory platform fee, which most comparison tables do not add back.

Pricing2026-05-20

Short answer

Several programs now split the charge into medication plus a mandatory platform fee, which most comparison tables do not add back.

An increasing share of programs bill medication and a mandatory membership separately. Ivim charges $74.99 on top of $133 medication. Mochi charges $79 on top of $199. Eden charges $99 on top of its medication price. Found and Ro use the same structure.

Comparison tables that quote the medication figure alone make these programs look far cheaper than they are. Ivim advertised at $133 is $208 all-in; Mochi at $199 is $278.

Every price on this site is stated all-in — medication plus any recurring fee — at a named dose. That is why some of our numbers are higher than the same program's homepage, and it is deliberate.

Before enrolling anywhere, ask one question: what will I pay in total in month six at 10 mg, including every fee. A program that cannot answer that in one sentence is telling you something.

Sources

  1. Provider published pricing pages, accessed August 2026

Dated 2026-05-20. If this item is out of date or wrong, tell us through contact and the change is logged in corrections.

Price your actual dose

Six dose tiers, sixteen tracked programs, twelve-month totals.

Open the calculator

Primary sources

Clinical, dosing and regulatory statements on this page rest on the documents below. Links go to the publisher, not to a summary of it. Prices are not sourced here — they carry a verification date instead, and the reason is set out in the source ledger.

  1. ZEPBOUND (tirzepatide) full prescribing information — DailyMed, US National Library of Medicine. Dose ladder, contraindications, warnings, storage.
  2. FDA’s concerns with unapproved GLP-1 drugs used for weight loss — US Food and Drug Administration. Compounded GLP-1 risks, API import alert, cold-chain complaints.
  3. FD&C Act provisions that apply to human drug compounding — US Food and Drug Administration. Why a compounded preparation is lawful without being FDA-approved.
  4. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — N Engl J Med 2022;387:205-216. Registration NCT04184622. The weight-reduction and adverse-event figures used across this site.
  5. The full source ledger — every primary source, what it supports, the date we read it, and the claims we deliberately do not source.